Filing Flows › Collegium Pharmaceutical (COLL) › Q3 2026 › vs Q2 2026
Collegium Pharmaceutical (COLL) Q3 2026 vs Q2 2026 (quarter over quarter)
Collegium Pharmaceutical's revenue rose $16.5M (+8%) from $200M in Q2 2026 to $216M in Q3 2026. The biggest changes: Azstarys +$13.6M (+105%); Nucynta ER −$5.8M (-37%); Jornay PM +$5.8M (+13%). Gross margin 58.0% against 55.2% (+2.8 pts).
Collegium Pharmaceutical, Q3 2026: revenue $216M (+3% year over year), operating margin 13.3%, net earnings $21.8M, operating cash flow $86.5M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 58.0% | 55.2% | +2.8 pts |
| Operating margin | 13.3% | 1.9% | +11.4 pts |
| Net margin | 10.1% | -7.5% | +17.6 pts |
| Free cash flow margin | 39.9% | 35.4% | +4.4 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Belbuca | $57.7M | $57.7M | $51K | +0.1% |
| Jornay PM | $51.9M | $46.1M | $5.8M | +13% |
| Xtampza ER | $45.8M | $45.0M | $810K | +2% |
| Azstarys | $26.5M | $12.9M | $13.6M | +105% |
| Nucynta IR | $16.7M | $14.4M | $2.4M | +16% |
| Nucynta ER | $9.9M | $15.7M | −$5.8M | -37% |
| Nucynta ER AG | $3.9M | $2.8M | $1.1M | +40% |
| Symproic | $3.6M | $3.0M | $604K | +20% |
| Revenue | $216M | $200M | $16.5M | +8% |
| Gross profit | $125M | $110M | $15.1M | +14% |
| Cost of revenue | $90.9M | $89.6M | $1.3M | +1% |
| Operating profit | $28.7M | $3.7M | $25.0M | +677% |
| Operating expenses | $96.7M | $107M | −$9.9M | -9% |
| Pre-tax earnings | $7.9M | −$13.5M | $21.4M | — |
| Other expense, net | $20.8M | $17.2M | $3.6M | +21% |
| Income tax benefit | $13.9M | −$1.5M | $15.4M | — |
| Net earnings | $21.8M | −$15.1M | $36.8M | — |
| Depreciation & amortization | $55.8M | $64.8M | −$8.9M | -14% |
| Share-based compensation | $12.4M | $14.5M | −$2.0M | -14% |
| Working capital & other | $3.5M | −$7.1M | $10.6M | — |
| Operating cash flow | $86.5M | $71.3M | $15.2M | +21% |
| Free cash flow (OCF − capex) | $86.3M | $70.8M | $15.4M | +22% |
| Capital expenditures | $277K | $496K | −$219K | -44% |
Questions
How much did Collegium Pharmaceutical's revenue grow quarter over quarter in Q3 2026?
Collegium Pharmaceutical's revenue rose $16.5M (+8%) from $200M in Q2 2026 to $216M in Q3 2026.
What drove Collegium Pharmaceutical's revenue change in Q3 2026?
Azstarys +$13.6M (+105%); Nucynta ER −$5.8M (-37%); Jornay PM +$5.8M (+13%).